Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...